Study backs T-wave alternans test:
This article was originally published in Clinica
Measuring T-wave alternans, subtle beat-to-beat fluctuations in heartbeat, could help predict ventricular tachycardia (VT) in patients with non-ischaemic dilated cardiomyopathy (DCM), according to a study published in the Journal of the American College of Cardiology (August). The sensitivity, specificity and predictive accuracy of T-wave alternans for VT in 58 patients with DCM were 88%, 72% and 77% respectively. US company Cambridge Heart of Bedford, Massachusetts, which makes the only non-invasive T-wave alternans test with FDA clearance, said the findings were significant since a conventional electrophysiology study is not considered useful in diagnosing patients with non-ischaemic DCM.
You may also be interested in...
COVID-19 Vaccines: ACIP’s Allocation Proposal Prioritizes Long-Term Care Residents, Essential Workers
First group to receive vaccine would comprise health care personnel and residents of long-term care facilities; next in line are non-health care essential workers, who would take priority over adults with high-risk medical conditions and those ages 65 years and older, according to the CDC advisory committee’s proposed allocation framework.
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.